Mineralys Therapeutics (MLYS) Stock Price, News & Analysis

Company Overview

Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for fibroinflammatory diseases of the liver and kidney. The company’s proprietary platform centers on small-molecule soluble guanylate cyclase (sGC) modulation, aiming to restore normal vascular and immune cell function to address underlying drivers of chronic organ damage. Mineralys’ lead programs include MLY-402 for portal hypertension secondary to cirrhosis and MLY-127 for diabetic kidney disease, both of which have advanced into clinical studies.

Since its inception, Mineralys has built a diversified pipeline that spans from early discovery through Phase 2 development. The research team leverages in-house target validation, medicinal chemistry, and translational biology capabilities to optimize sGC modulators with differentiated pharmacokinetic and safety profiles. Beyond its lead assets, the company is exploring additional indications where impaired nitric oxide signaling and fibrosis intersect, including nonalcoholic steatohepatitis (NASH) and select rare kidney disorders.

Headquartered in Cambridge, Massachusetts, Mineralys operates research facilities in the Boston biotech hub while maintaining collaborations with leading academic institutions and contract research organizations worldwide. This geographic reach enables the company to conduct multi-center clinical trials across North America and Europe, accelerating patient enrollment and regulatory interactions. The global footprint also supports future commercial readiness in key markets.

Mineralys is led by an experienced management team with deep industry expertise spanning drug discovery, clinical development, regulatory affairs, and commercialization. The leadership includes veterans from both large pharmaceutical companies and successful biotech startups, supported by a scientific advisory board of renowned hepatology and nephrology experts. Together, they guide Mineralys toward its mission of delivering first-in-class therapies for patients with debilitating liver and kidney diseases.

Key Stats

• Today's Range: $14.40 to $15.24
• 50-Day Range: $13.45 to $16.66
• 52-Week Range: $8.24 to $18.38
• Volume: 316,141 shs
• Average Volume: 554,994 shs
• Market Capitalization: $952.93 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $32.25
• Consensus Rating: Moderate Buy

Mineralys Therapeutics Stock Analysis - MarketRank™

Mineralys Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 616th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Mineralys Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Mineralys Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Mineralys Therapeutics are expected to decrease in the coming year, from ($4.23) to ($4.48) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Mineralys Therapeutics is -3.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mineralys Therapeutics is -3.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Mineralys Therapeutics has a P/B Ratio of 3.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

18.89% of the float of Mineralys Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Mineralys Therapeutics has a short interest ratio ("days to cover") of 9.2.

Change versus previous month

Short interest in Mineralys Therapeutics has recently increased by 24.31%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mineralys Therapeutics does not currently pay a dividend.

Dividend Growth

Mineralys Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

18.89% of the float of Mineralys Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Mineralys Therapeutics has a short interest ratio ("days to cover") of 9.2.

Change versus previous month

Short interest in Mineralys Therapeutics has recently increased by 24.31%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 1.18

News Sentiment

Mineralys Therapeutics has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Mineralys Therapeutics this week, compared to 4 articles on an average week.

MarketBeat Follows

Only 2 people have added Mineralys Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Mineralys Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $173,786.00 in company stock.

Percentage Held by Insiders

33.24% of the stock of Mineralys Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

84.46% of the stock of Mineralys Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MLYS Stock Analysis - Frequently Asked Questions

How have MLYS shares performed this year?

Mineralys Therapeutics' stock was trading at $12.31 at the start of the year. Since then, MLYS shares have increased by 18.8% and is now trading at $14.62.

How were Mineralys Therapeutics' earnings last quarter?

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) posted its earnings results on Monday, May, 12th. The company reported ($0.79) earnings per share for the quarter, beating the consensus estimate of ($1.02) by $0.23.
Read the conference call transcript.

When did Mineralys Therapeutics IPO?

Mineralys Therapeutics (MLYS) raised $180 million in an initial public offering on Friday, February 10th 2023. The company issued 12,000,000 shares at $14.00-$16.00 per share.

Who are Mineralys Therapeutics' major shareholders?

Mineralys Therapeutics' top institutional shareholders include Swedbank AB (0.59%). Insiders that own company stock include Brian Taylor Slingsby, Samsara Biocapital Gp, Llc, Ra Capital Management, LP, Hbm Healthcare Investments (Ca, Jon Congleton, Adam Scott Levy and David Malcom Rodman.
View institutional ownership trends.

How do I buy shares of Mineralys Therapeutics?

Shares of MLYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Mineralys Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mineralys Therapeutics investors own include Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/15/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MLYS
• CIK: 1933414
• Web: www.mineralystx.com
• Phone: 888-378-6240
• Fax: N/A
• Employees: 28
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Mineralys Therapeutics: $32.25
• High Price Target: $48.00
• Low Price Target: $15.00
• Potential Upside/Downside: +120.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.73)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$177.81 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -71.15%
• Return on Assets: -65.71%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 26.48
• Quick Ratio: 26.48

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.84 per share
• Price / Book: 3.81

Miscellaneous

• Outstanding Shares: 65,180,000
• Free Float: 43,511,000
• Market Cap: $952.93 million
• Optionable: Optionable
• Beta: -0.30